Raj Anuradha, Singla Anurag, Sidana Shivani
Department of Ophthalmology, All India Institute of Medical Sciences, Bathinda, Punjab, India.
Department of Endocrinology, All India Institute of Medical Sciences, Bathinda, Punjab, India.
Curr Diab Rep. 2025 Jun 10;25(1):36. doi: 10.1007/s11892-025-01591-5.
To highlight various preventive and therapeutic strategies via health care delivery system to minimize sight-threatening diabetic retinopathy.
Diabetic retinopathy (DR) is a common and specific microvascular complication of diabetes and is a common cause of blindness among economic age groups or the working population of the country. Clinically, DR can be graded as non-sight-threatening diabetic retinopathy (NSTDR), including mild and moderate non-proliferative abnormalities and sight-threatening diabetic retinopathy (STDR), which comprises of severe non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), or clinically significant macular edema (CSME). In STDR, the disease progresses to the proliferative phase which is characterized by the formation of new blood vessels and macular edema owing to the accumulation of fluid within the retina, producing severe and often irreversible vision loss. With the influx of artificial intelligence in the medical arena, there is a continuous rise in the demand for the development of automated analysis software for the analysis of retinal images in people with diabetes. Nowadays, Smartphone-based retinal imaging has emerged as one of the most cost-effective ways of screening for DR in the community, which even non-ophthalmologists can do. Understanding the factors associated with STDR can help to develop primary and secondary prevention strategies. Spreading awareness regarding STDR at the community level is crucial. All diabetic patients need regular and repetitive follow-ups with the ophthalmologist for screening and timely treatment of DR, particularly STDR. Preservation of sight in STDR can be achieved through effective screening, timely laser treatment, intraocular injection of steroids and anti-vascular endothelial growth-factor agents and intraocular surgery.
强调通过医疗保健系统采取的各种预防和治疗策略,以尽量减少威胁视力的糖尿病视网膜病变。
糖尿病视网膜病变(DR)是糖尿病常见且特定的微血管并发症,是该国经济活跃年龄段或劳动人口失明的常见原因。临床上,DR可分为非威胁视力的糖尿病视网膜病变(NSTDR),包括轻度和中度非增殖性异常,以及威胁视力的糖尿病视网膜病变(STDR),后者包括重度非增殖性糖尿病视网膜病变(NPDR)、增殖性糖尿病视网膜病变(PDR)或临床显著性黄斑水肿(CSME)。在STDR中,疾病进展到增殖期,其特征是由于视网膜内液体积聚形成新血管和黄斑水肿,导致严重且通常不可逆的视力丧失。随着人工智能涌入医学领域,对开发用于分析糖尿病患者视网膜图像的自动化分析软件的需求持续上升。如今,基于智能手机的视网膜成像已成为社区筛查DR最具成本效益的方法之一,甚至非眼科医生也能操作。了解与STDR相关的因素有助于制定一级和二级预防策略。在社区层面提高对STDR的认识至关重要。所有糖尿病患者都需要定期反复接受眼科医生的随访,以筛查和及时治疗DR,尤其是STDR。通过有效的筛查、及时的激光治疗、眼内注射类固醇和抗血管内皮生长因子药物以及眼内手术,可以在STDR中保留视力。